Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 6/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formamide SCHEMBL5126384 | 0.88 | MAPT (0.41) | DRD2TRPA1TRPV1MAPTMALT1 | |
| Formamide SCHEMBL5122603 | 0.88 | CXCR3 (0.40) | TRPV1SMN1; SMN2 | |
| SCHEMBL1457235 | 0.82 | TRPV1 (0.48) | TRPA1TRPV1MALT1CNR2 | |
| SCHEMBL1457227 | 0.81 | P2RY12 (0.45) | TRPA1TRPV1SMN1; SMN2CNR2 | |
| Formamide SCHEMBL5118917 | 0.75 | SMN1; SMN2 (0.43) | MAPTSMN1; SMN2CNR2 | |
| SCHEMBL1457231 | 0.74 | TRPV1 (0.50) | TRPA1TRPV1 | |
| SCHEMBL15397894 | 0.72 | TRPA1 (0.46) | TRPA1TRPV1 | |
| SCHEMBL1457523 | 0.70 | P2RY12 (0.48) | TRPA1TRPV1SMN1; SMN2 | |
| SCHEMBL15397892 | 0.69 | TRPA1 (0.47) | TRPA1TRPV1 | |
| SCHEMBL5115851 | 0.68 | TRPA1 (0.46) | TRPA1TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214807-A1 | Substituted Spiro Compounds and their Use for Producing Drugs | GRUENENTHAL GMBH (DE) | 2008-09-04 | — | — | US | claimed |
| US-20080214807-A1 | Substituted Spiro Compounds and their Use for Producing Drugs | GRUENENTHAL GMBH (DE) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214807-A1 | Substituted Spiro Compounds and their Use for Producing Drugs | REN, PKD1, NR3C2 | DRD2 698/4885DRD1 884/4885TRPA1 720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.